Dr. Kamran on including immunotherapy in bladder-preservation therapy

Video

“The NRG SWOG 1806 trial is a phase 3 trial randomizing patients to standard trimodality therapy or trimodality therapy plus atezolizumab,” says Sophia Kamran, MD.

Sophia Kamran, MD, discusses the potential of adding immune-checkpoint inhibitors, such as the PD-L1 inhibitor atezolizumab (Tecentriq) to bladder-preservation, or “trimodal,” therapy for patients with bladder cancer. Kamran is a radiation oncologist at Massachusetts General Hospital and assistant professor of Radiation Oncology at Harvard Medical School.

Related Videos
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Dr. Kyle A. Richards in an interview with Urology Times
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.